Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, transporters, and viral envelopes. The Company has over a decade of experience in optimizing membrane proteins, enabling the isolation, characterization, and engineering of monoclonal antibodies against otherwise intractable membrane protein targets. Integral Molecular has worked with over 100 different partners and customers, including all of the top 10 pharmaceutical companies.
Integral membrane proteins include some of the most important therapeutic targets. Yet these types of proteins are very difficult to study due to their structural complexity and inability to be removed from the lipid membrane in conformationally-intact states. At Integral Molecular, we develop innovative technologies and products that address these demanding yet important targets.
Founded in 2001, Integral Molecular holds intellectual property rights covering all aspects of its technologies, including core patents licensed exclusively from the University of Pennsylvania.
Integral Molecular operates a 10,000-square-foot facility equipped with state-of-the-art molecular biology, cell culture, high-throughput robotics, biosensor, and flow cytometry instrumentation for a wide range of discovery capabilities. Integral Molecular is strategically located in the heart of Philadelphia’s University City Science Center within walking distance of $1B of scientific research, infrastructure, and expertise at the University of Pennsylvania, Drexel University, Children’s Hospital of Philadelphia, Wistar Institute, and Thomas Jefferson University.
Benjamin Doranz, Ph.D., MBA
President and CEO
Dr. Doranz is an established life science entrepreneur previously responsible for directing the biotechnology program at the Port of Technology business incubator in Philadelphia and helping create startups at the Center for Technology Transfer at the University of Pennsylvania. Dr. Doranz earned a Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania where he led the discovery of the coreceptor for HIV (CCR5), an MBA at the Wharton School of Business where he won the business plan competition and co-founded the Penn Biotech Group, and a B.A. at Cornell University.
Joseph Rucker, Ph.D.
VP of Research and Development
Dr. Rucker’s expertise focuses on membrane proteins, antibodies, and viruses. He is an author on over 30 publications and has published in journals including Cell, Science, and Nature. He is an inventor on five of the company’s patents and is the principal investigator on many of Integral’s NIH-funded projects. Dr. Rucker earned his Ph.D. in Chemistry from the University of California, Berkeley and his B.A. at Haverford College. As a post-doc at the University of Pennsylvania, he was involved in leading the discovery of the GPCR CCR5 as an HIV coreceptor.
Sharon Willis, Ph.D.
VP of Sales and Customer Relations
Dr. Willis is an adjunct professor in the Biology Department at Drexel University and a member of the Advisory Committee for the Biomedical Technical Training Program at the Wistar Institute. She is also a member of the External Advisory Board for the Chemistry Department at the University of North Carolina, Chapel Hill. Dr. Willis earned her Ph.D. in Chemistry from the University of North Carolina, Chapel Hill and her B.A. cum laude from Gettysburg College. As a post-doc at the University of Pennsylvania, she studied membrane-enveloped viruses and solved the crystal structure of the cellular receptor for HSV (gD-HVEM).
Ross Chambers, Ph.D.
Director of Antibody Discovery
Dr. Chambers was previously the Director of Research and Development at SDIX, where he directed the discovery of thousands of commercial antibodies using DNA immunization, B cell cloning, and other isolation techniques. Before that he developed DNA immunization for large-scale antibody isolation projects at UT Southwestern. Dr. Chambers earned his Ph.D. from the University of Otago, New Zealand, and completed post-docs at UC Davis and Berkeley.